Use of Tenofovir Diphosphate Levels to Predict Viremia During the Postpartum Period in Women Living With Human Immunodeficiency Virus (HIV): A Nested Case-Control Study.
adherence
antiretroviral therapy
dried blood spots
predictive value
tenofovir diphosphate
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
14 09 2022
14 09 2022
Historique:
received:
19
10
2021
pubmed:
4
1
2022
medline:
20
9
2022
entrez:
3
1
2022
Statut:
ppublish
Résumé
There are few data on the utility of tenofovir diphosphate (TFV-DP) in dried blood spots (DBSs) to predict future viral load (VL) in postpartum women with HIV on antiretroviral therapy (ART). We conducted a nested case-control study within a trial of postpartum ART delivery strategies. Participants started ART containing tenofovir disoproxil fumarate (TDF) in pregnancy, were <10 weeks postpartum, and had a VL <400 copies/mL. VL and TFV-DP samples were taken every 3-6 months over 24 months. Cases had ≥1 VL ≥20 copies/mL; controls were randomly sampled from women with persistent viral suppression (VS; VL <20 copies/mL). Generalized estimating equations were used to calculate likelihood odds ratios (LORs) for future VL ≥20 copies/mL by TFV-DP concentration at the preceding visit. 61 cases and 20 controls contributed 365 DBS-VL pairs (median ART duration, 16 months). Sensitivity and specificity of TFV-DP <700 fmol/punch to detect future viremia were 62.9% (95% CI, 54.7-70.6%) and 89.7% (84.9-93.4%), respectively. Adjusting for age, ART duration, previous VL, and duration between the TFV-DP and VL measures, LORs of viremia for TFV-DP concentrations 350-699 and <350 fmol/punch versus TFV-DP ≥1850 fmol/punch were 3.5 (95% CI, 1.1-10.8; P = .033) and 12.9 (3.6-46.6; P < .0001), respectively. Including only samples taken during VS, the LOR of future viremia for TFV-DP concentration <350 fmol/punch versus TFV-DP ≥1850 fmol/punch was 9.5 (1.9-47.0). TFV-DP concentrations in DBSs were strongly associated with future viremia and appear useful to identify nonadherence and predict future elevated VL.
Sections du résumé
BACKGROUND
There are few data on the utility of tenofovir diphosphate (TFV-DP) in dried blood spots (DBSs) to predict future viral load (VL) in postpartum women with HIV on antiretroviral therapy (ART).
METHODS
We conducted a nested case-control study within a trial of postpartum ART delivery strategies. Participants started ART containing tenofovir disoproxil fumarate (TDF) in pregnancy, were <10 weeks postpartum, and had a VL <400 copies/mL. VL and TFV-DP samples were taken every 3-6 months over 24 months. Cases had ≥1 VL ≥20 copies/mL; controls were randomly sampled from women with persistent viral suppression (VS; VL <20 copies/mL). Generalized estimating equations were used to calculate likelihood odds ratios (LORs) for future VL ≥20 copies/mL by TFV-DP concentration at the preceding visit.
RESULTS
61 cases and 20 controls contributed 365 DBS-VL pairs (median ART duration, 16 months). Sensitivity and specificity of TFV-DP <700 fmol/punch to detect future viremia were 62.9% (95% CI, 54.7-70.6%) and 89.7% (84.9-93.4%), respectively. Adjusting for age, ART duration, previous VL, and duration between the TFV-DP and VL measures, LORs of viremia for TFV-DP concentrations 350-699 and <350 fmol/punch versus TFV-DP ≥1850 fmol/punch were 3.5 (95% CI, 1.1-10.8; P = .033) and 12.9 (3.6-46.6; P < .0001), respectively. Including only samples taken during VS, the LOR of future viremia for TFV-DP concentration <350 fmol/punch versus TFV-DP ≥1850 fmol/punch was 9.5 (1.9-47.0).
CONCLUSIONS
TFV-DP concentrations in DBSs were strongly associated with future viremia and appear useful to identify nonadherence and predict future elevated VL.
Identifiants
pubmed: 34979553
pii: 6494527
doi: 10.1093/cid/ciab1068
pmc: PMC9477450
doi:
Substances chimiques
Anti-HIV Agents
0
Organophosphates
0
tenofovir diphosphate
0
Tenofovir
99YXE507IL
Adenine
JAC85A2161
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
761-767Subventions
Organisme : Medical Research Council
ID : MR/M007464/1
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : R01 AI145453
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068634
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW010559
Pays : United States
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Déclaration de conflit d'intérêts
Potential conflicts of interest. C. O. reports honoraria for consultation on special interest groups with MSD and ViiV Healthcare. J. C.-M. reports payment or honoraria from Practice Point CME. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Références
Clin Infect Dis. 2017 Feb 15;64(4):422-427
pubmed: 27927852
PLoS Med. 2017 Aug 15;14(8):e1002375
pubmed: 28809929
J Pharm Biomed Anal. 2011 Sep 10;56(2):390-401
pubmed: 21715120
Contemp Clin Trials Commun. 2019 Aug 22;16:100442
pubmed: 31709309
J Acquir Immune Defic Syndr. 2017 Jun 1;75 Suppl 2:S115-S122
pubmed: 28498180
Clin Infect Dis. 2019 Apr 8;68(8):1335-1342
pubmed: 30137238
PLoS One. 2013 Oct 25;8(10):e78287
pubmed: 24205183
Int J Epidemiol. 2009 Jun;38(3):746-56
pubmed: 19223334
Ther Adv Infect Dis. 2021 May 14;8:20499361211010596
pubmed: 34035910
AIDS Behav. 2006 May;10(3):227-45
pubmed: 16783535
J Acquir Immune Defic Syndr. 2019 Jul 1;81(3):311-318
pubmed: 30893125
Transl Behav Med. 2015 Dec;5(4):470-82
pubmed: 26622919
J Acquir Immune Defic Syndr. 2020 Jan 1;83(1):72-80
pubmed: 31651545
AIDS. 2014 Jan 2;28(1):59-66
pubmed: 24275255
Clin Pharmacokinet. 2014 Nov;53(11):961-73
pubmed: 25204403
AIDS Res Hum Retroviruses. 2013 Feb;29(2):384-90
pubmed: 22935078
J Acquir Immune Defic Syndr. 2002 Dec 15;31 Suppl 3:S112-7
pubmed: 12562032
J Infect Dis. 2019 Jul 19;220(4):635-642
pubmed: 30942881
Antimicrob Agents Chemother. 2017 Dec 21;62(1):
pubmed: 29038282
BMC Infect Dis. 2019 Sep 16;19(Suppl 1):789
pubmed: 31526366
J Int Assoc Provid AIDS Care. 2019 Jan-Dec;18:2325958219888457
pubmed: 31750768
Curr HIV/AIDS Rep. 2020 Aug;17(4):301-314
pubmed: 32424549
AIDS. 2012 Oct 23;26(16):2039-52
pubmed: 22951634